Fig. 3

miR-326-3p and miR-339-3p are up-regulated in senescent EAT derived LEVs. A Diagram of assays used to identify content encapsulated by senescent EAT derived LEVs in vivo and ex vivo. B Gene ontology biological process (BP) enrichment analysis of predicted target genes of differentially expressed LEV-miRNAs. C IPA analysis for pathological pathway enrichment of differentially expresses genes in RNA-seq. D Representative image of venn analysis between differentially expressed genes in AMVM versus differentially expressed miRNA target genes of LEVs. E Expression level of miRNA in EAT culture medium of Con- or STZ- EAT-LEVs (n = 4–6 per group). F Expression level of miRNA in Veh or Seno treated STZ-EAT LEVs collected from adipose tissue conditioned medium (n = 3 per group). G Expression levels of miRNA-326-3p and miRNA-339-3p in NMVMs treated with Con- or STZ-EAT LEVs (n = 5 per group). H Expression level of miRNA in NMVMs treated with LEVs from STZ-EAT cultured ex vivo in presence of Seno or Veh (n = 3 per group). I Expression levels of miRNA-339-3p (left) and miRNA-326-3p (right) in murine blood LEVs from control group, STZ + Sham group and STZ + EATr group. (n = 4 per group). J Expression levels of miRNA-326-3p and miRNA-339-3p in AMVMs isolated from control group, STZ + Sham group or STZ + EATr group (n = 5 per group). Data are presented as the mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001 compared to Con group; ^#P < 0.05, ^##P < 0.01 compared to Veh group; ^$P < 0.05, ^$$P < 0.01 compared to STZ + EATr group